Premium
P1‐378: EFFECT OF PHOSPHODIESTERASE 5 INHIBITORS ON COGNITIVE DECLINE: RETROSPECTIVE ANALYSIS OF EXPOSURE IN ADNI PARTICIPANTS
Author(s) -
SénéchalDumais Isabelle,
Duchesne Simon
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.620
Subject(s) - cognitive decline , medicine , wilcoxon signed rank test , cohort , proportional hazards model , cognition , log rank test , psychology , dementia , psychiatry , mann–whitney u test , disease
patients (63.6%) who received donepezil 10 mg/d ay. The 3 most common AEs reported with the 23 mg/d ay vs 10mg/day were nausea (13[22%] vs 2 [6.1%], vomiting (10[16.9%] vs 2[6.1%]) and epigastric discomfort (3 [5.1%] vs 0[0%]). The rate of serious AEs for donepezil23-mg/d vs donepezil 10-mg/d was higher for donepezil 10-mg/d (3.4% vs 15.2%). Conclusions: In this Korean population subanalysis, patients with moderate to severe AD, donepezil 23 mg/d ay had numerically greater benefits in cognition versus donepezil 10 mg/d ay. Donepezil 23 mg/d group had numerically higher discontinuation rates. Caution is required in patients with body weight < 55 kg as they may encounter higher adverse events. The subanalysis confirms the efficacy and tolerability of donepezil 23 mg/day to donepezil 10 mg/day and is comparable to that of global study.